The effect of Edaravone on clinical symptoms and oxidative stress factors in patients with acute ischemic stroke: A clinical trial

Khazaei, Mojtaba; Saadati Pour, Fatemeh; Ghiasian, Masoud; Khazaei, Salman; Mazaheri, Shahir; Ranjbar, Akram; Daneshyar, Sajjad; Nazifi, Mozhgan

doi:10.48307/FMSJ.2024.28.2.167

[Home ] [Archive]

[ فارسی ]

Main Menu

Home

Journal Information

Indexing Sources

Guide for Authors

Online Submission

Ethics

Articles archive

For Reviewers

Contact us

Biochemistry and Nutrition in Metabolic Diseases

DOAJ

CINAHL

EBSCO

IMEMR

ISC

Search in website

Receive site information

enamad

Volume 28, Issue 2 (Bimonthly 2024)

Feyz Med Sci J 2024, 28(2): 167-173

Back to browse issues page

The effect of Edaravone on clinical symptoms and oxidative stress factors in patients with acute ischemic stroke: A clinical trial

Mojtaba Khazaei

, Fatemeh Saadati Pour

, Sajjad Daneshyar ^*

, Mozhgan Nazifi

Department of Neurology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran , s.danshyar72@yahoo.com

Abstract: (377 Views)

Background and Aim: Edaravone is known for its efficacy in inhibiting free radical formation, activating microglia, and promoting neurogenesis and neuroprotection following acute ischemic stroke. This clinical trial aimed to investigate the effects of Edaravone on clinical symptoms and oxidative stress factors in patients with acute ischemic stroke.
Methods: In this clinical trial, fifty-two patients diagnosed with acute ischemic stroke were randomly assigned to receive either Edaravone (120 mg daily up to 3 doses intravenously) or a placebo in addition to standard treatment. Stroke severity was assessed using the NIH Stroke Scale (NIHSS) and Modified Rankin Scale (MRS) at hospitalization and three months post-stroke. Antioxidant capacity, protein oxidation, and lipid peroxidation levels were measured during hospitalization and three days later.
Results: Twenty-six patients were included in each group and were matched in terms of risk factors, neurological symptom severity, antioxidant capacity, protein oxidation, and lipid peroxidation at hospitalization. At the three-month follow-up, both groups showed a decrease in neurological symptom severity, with a slightly higher reduction observed in the Edaravone group, though not statistically significant (P=0.256). A similar proportion of patients achieved an MRS score of ≤2 within three months post-stroke in both groups (23.1% in the placebo group vs. 30.8% in the Edaravone group, P=0.755). All eight deaths within the first three months occurred in the placebo group. The most common side effect was intracerebral hemorrhage (13.5%), predominantly in the placebo group. Despite higher mean antioxidant capacities in the intervention group, no significant difference was observed post-intervention.
Conclusion: The study suggests that adding Edaravone to standard treatment for acute ischemic stroke may lead to improved patient outcomes. However, further research with larger sample sizes is needed to establish the efficacy of this medication.

Keywords: Acute ischemic stroke, Edaravone, Oxidative stress, Antioxidants

Full-Text [PDF 404 kb] (214 Downloads)

Type of Study: Research | Subject: medicine, paraclinic
Received: 2024/01/20 | Revised: 2024/08/18 | Accepted: 2024/02/29 | Published: 2024/06/2

References

1. Rowland LP, Pedley TA. Merritt's Neurology. 12 ed. Houston: Lippincott Williams & Wilkins; 2010.

2. Greenberg D, Aminoff M, Simon R. Clinical Neurology. 8 ed. New York: McGraw HillProfessional; 2012.

3. Ropper AH, Samuels MA, Victor's A. principles of neurology. 10 ed. New York: MC Graw Hill; 2013.

4. Chapman SN, Mehndiratta P, Johansen MC, McMurry TL, Johnston KC, Southerland AM. Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke. Vascular health and risk management. 2014; 10: 75-87. doi:10.2147/VHRM.S39213 PMid:24591838 PMCid:PMC3938499

5. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke; a journal of cerebral circulation. 2013;44(3):870-947. doi:10.1161/STR.0b013e318284056a PMid:23370205

6. Saini V, Guada L, Yavagal DR. Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions. Neurology. 2021; 97(20 Suppl 2): S6-s16. doi:10.1212/WNL.0000000000012781 PMid:34785599

7. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke; a journal of cerebral circulation. 1988;19(4):480-5. doi:10.1161/01.STR.19.4.480 PMid: 2834836

8. Shakkour Z, Issa H, Ismail H, Ashekyan O, Habashy KJ, Nasrallah L, et al. Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury. Curr Med Chem. 2021; 28(12): 2369-91. doi:10.2174/0929867327666200812221022 PMid:32787753

9. Tanahashi N, Yamaguchi T, Awano H, Matsuda H. Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. J Stroke Cerebrovascular Dis. 2018;27(5):1302-10. doi:10.1016/j.jstrokecerebrovasdis.2017.12.019 PMid:29373227

10. Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? Journal of clinical biochemistry and nutrition. 2018:17-62. doi:10.3164/jcbn.17-62 PMid:29371752 PMCid:PMC5773834

11. Kobayashi S, Fukuma S, Ikenoue T, Fukuhara S, Kobayashi S. Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke. Stroke. 2019;50(7):1805-11. doi:10.1161/STROKEAHA.118.024351 PMid:31164072

12. Feng S, Yang Q, Liu M, Li W, Yuan W, Zhang S, et al. Edaravone for acute ischaemic stroke. Cochrane Database Syst Rev. 2011; (12): Cd007230. doi:10.1002/14651858.CD007230.pub2 PMid:22161410

13. Yang J, Cui X, Li J, Zhang C, Zhang J, Liu M. Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials. Dev Neurorehabil. 2015;18(5):330-5. doi:10.3109/17518423.2013.830153 PMid:24088023

14. Zhao K, Li GZ, Nie LY, Ye XM, Zhu GY. Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis. Clin Ther. 2022; 44(12): e29-e38. doi:10.1016/j.clinthera.2022.11.005 PMid: 36473732

15. Qin M, Feng L, Yang C, Wei D, Li T, Jiang P, et al. Edaravone use in acute intracerebral hemorrhage: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022; 13:935198. doi:10.3389/fphar.2022.935198 PMid: 36034840 PMCid:PMC9412023

16. Lee XR, Xiang GL. Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator. Clin Neurol Neurosurg. 2018; 167:157-61. doi:10.1016/j.clineuro.2018.02.026 PMid:29501045

17. Chen C, Li M, Lin L, Chen S, Chen Y, Hong L. Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2021; 46(4): 907-17. doi:10.1111/jcpt.13392 PMid: 33638896 PMCid:PMC8359409

18. Edaravone Acute Infarction Study Group. Effect of a novel free radicalscavenger, edaravone (MCI-186), on acute brain infarction. Randomized,placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003; 15: 222-9. doi:10.1159/000069318 PMid:12715790

19. Xu J, Wang Y, Wang A, Gao Z, Gao X, Chen H, et al. Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial. Stroke Vasc Neurol. 2019; 4(3):109-14. doi:10.1136/svn-2018-000221 PMid:31709115 PMCid:PMC6812637

20. Xu J, Wang A, Meng X, Yalkun G, Xu A, Gao Z, et al. Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. Stroke 2021; 52(3): 772-80. doi:10.1161/STROKEAHA.120.031197 PMid:33588596

21. Mozafari F, Rashidzadeh H, Bijani S, Zare-Molaei F, Islambulchilar Z, Danafar H, et al. Enhancing the Neuroprotection Potential of Edaravone in Transient Global Ischemia Treatment with Glutathione- (GSH-) Conjugated Poly(methacrylic acid) Nanogel as a Promising Carrier for Targeted Brain Drug Delivery. Oxid Med Cell Longev. 2023; 2023: 7643280. doi:10.1155/2023/7643280 PMid:36865347 PMCid:PMC9974254

Send email to the article author

Add your comments about this article

‎ 10.48307/FMSJ.2024.28.2.167

Mendeley

Zotero

RefWorks

Khazaei M, Saadati Pour F, Ghiasian M, Khazaei S, Mazaheri S, Ranjbar A, et al . The effect of Edaravone on clinical symptoms and oxidative stress factors in patients with acute ischemic stroke: A clinical trial. Feyz Med Sci J 2024; 28 (2) :167-173
URL: http://feyz.kaums.ac.ir/article-1-5105-en.html

This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.

Volume 28, Issue 2 (Bimonthly 2024)

Back to browse issues page

Persian site map - English site map - Created in 0.05 seconds with 46 queries by YEKTAWEB 4660